# A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

> **NCT02935686** · PHASE1,PHASE2 · COMPLETED · sponsor: **Janssen Vaccines & Prevention B.V.** · enrollment: 155 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** Ad26.Mos4.HIV
- **BIOLOGICAL:** Clade C gp140 plus adjuvant
- **BIOLOGICAL:** Clade C gp140/Mosaic gp140 plus adjuvant
- **OTHER:** Placebo
- **BIOLOGICAL:** gp140 HIV Bivalent Vaccine

## Key facts

- **NCT ID:** NCT02935686
- **Lead sponsor:** Janssen Vaccines & Prevention B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-31
- **Primary completion:** 2023-11-22
- **Final completion:** 2023-11-22
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2025-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02935686

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02935686, "A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02935686. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*